Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;9(8):1679-84.
doi: 10.4161/hv.24844. Epub 2013 May 31.

Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand

Yong Poovorawan  1 , Voranush Chongsrisawat, Apiradee Theamboonlers, Priya Diana Crasta, Marc Messier, Karin Hardt
Affiliations

Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand

Yong Poovorawan et al. Hum Vaccin Immunother. 2013 Aug.

Abstract

Hepatitis B vaccine has been available worldwide since the mid-1980s. This vaccine was evaluated in a clinical trial in Thailand, conducted on subjects born to hepatitis B surface antigen positive and hepatitis B e-antigen positive mothers and vaccinated according to a 4-dose schedule at 0, 1, 2 and 12 mo of age and a single dose of hepatitis B immunoglobulin concomitantly at birth. All enrolled subjects seroconverted and were followed for 20 y to assess the persistence of antibody to the hepatitis B surface antigen (anti-HBs) (NCT00240539). At year 20, 64% of subjects had anti-HBs antibody concentrations≥10 milli-international units per milli liter (mIU/ml) and 92% of subjects had detectable levels (≥3.3 mIU/ml) of anti-HBs antibodies. At year 20, subjects with anti-HBs antibody titer<100 mIU/ml were offered an additional dose of hepatitis B virus (HBV) vaccine to assess immune memory (NCT00657657). Anamnestic response to the challenge dose was observed in 96.6% of subjects with an 82-fold (13.2 to 1082.4 mIU/ml) increase in anti-HBs antibody geometric mean concentrations. This study confirms the long-term immunogenicity of the 4-dose regimen of the HBV vaccine eliciting long-term persistence of antibodies and immune memory against hepatitis B for up to at least 20 y after vaccination.

Keywords: challenge dose; hepatitis B; hepatitis B virus; persistence; vaccine.

PubMed Disclaimer

Figures

None
Figure 1. GMC evolution of anti-HBs antibodies from Month 1 to year 20 post-dose-1 in the unboosted group (LT-ATP cohort for immunogenicity).
None
Figure 2. Study design. This paper will not present the data on subjects boosted at Year-5 for long-term persistence since number of subjects in this group were low (n = 2), and these results do not provide any clinically relevant information. N, number of subjects in the LT-ATP cohort; N*, number of subjects in the ATP cohort for the challenge phase.
See this image and copyright information in PMC

References

    1. World Health Organization. Hepatitis B Vaccines. Wkly Epidemiol Rec 2009; 84:405-20. Available at: http://www.who.int/wer. Last accessed 26 February 2013.
    1. Heron L, Selnikova O, Moiseieva A, Van Damme P, van der Wielen M, Levie K, et al. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial. Vaccine. 2007;25:2817–22. doi: 10.1016/j.vaccine.2006.12.021. - DOI - PubMed
    1. Centers for Disease Control and Prevention (CDC) Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:868–70. - PubMed
    1. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135:796–800. doi: 10.7326/0003-4819-135-9-200111060-00009. - DOI - PubMed
    1. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Taiwan Childhood Hepatoma Study Group Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336:1855–9. doi: 10.1056/NEJM199706263362602. - DOI - PubMed

Substances

Associated data